Fluticasone furoate/umeclidinium/vilanterol - GlaxoSmithKline/Innoviva/Theravance Biopharma

Drug Profile

Fluticasone furoate/umeclidinium/vilanterol - GlaxoSmithKline/Innoviva/Theravance Biopharma

Alternative Names: Closed Triple; Elebrato Ellipta; FF/UMEC/VI; Fluticasone Furoate/Umeclidinium/Vilanterol Trifenatate; Fluticasone furoate/vilanterol/umeclidinium; GSK 2834425; GW 685698/GSK 573719/GW 642444; ICS/LABA/LAMA - GSK; ICS/LAMA/LABA - GSK; Trelegy Ellipta; UMEC/VI/FF; Umeclidinium/fluticasone furoate/vilanterol; Umeclidinium/vilanterol/fluticasone furoate; Vilanterol/fluticasone furoate/umeclidinium; Vilanterol/umeclidinium/fluticasone furoate

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline; Innoviva
  • Class Androstadienes; Benzhydryl compounds; Bronchodilators; Chlorobenzenes; Ethers; Glucocorticoids; Phenols; Quinuclidines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 05 Dec 2017 Fluticasone furoate/umeclidinium/vilanterol is still at Registered stage for Chronic obstructive pulmonary disease in USA (Inhalation) (GlaxoSmithKline website, December 2017)
  • 23 Nov 2017 GlaxoSmithKline and Innoviva file sNDA for treatment of patients with Chronic obstructive pulmonary disease (treatment of airflow obstruction and reduction of exacerbations) in USA
  • 16 Nov 2017 Registered for Chronic obstructive pulmonary disease in Liechtenstein, Iceland, Norway, European Union (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top